BioSpace News Archive

Used to stimulate motor nerves, muscle stimulation devices are set to witness surge in demand over the forecast period of 2019 to 2027.

extractX Ltd. (“extractX” or the “Company”), today announced financial results for the Company and its subsidiary extractX Incorporated (“EXI”) as at and for the three and nine months ended June 30, 2022.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the Gilmartin Group Inaugural Emerging Growth Company Showcase.

Ben Johnson, Senior Vice President of Programs at BioSTL, has been selected for a prestigious Eisenhower Fellowship through its 2022 USA Justice Fellows, a new program that sends mid-career American leaders abroad to enhance their perspectives and strategies for combatting entrenched racial discrimination in their own communities and professions.

Allarity Therapeutics, Inc. announced that on August 23, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC notifying the Company that it was not in compliance with requirements of Nasdaq Listing Rule 5250 as a result of not having timely filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, with the Securities and Exchange Commission.

Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focused on the development of innovative regenerative medicine and biological therapeutics, has closed its previously announced $4.0 million capital raise at $0.02 and corporate restructuring transaction.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2022 interim results.

The global small molecule API market is poised to grow at stupendous rate during the forecast period of 2019 to 2028.

ProSomnus Sleep Technologies (“ProSomnus”), the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the execution of definitive agreements with institutional investors led by funds affiliated with or managed by Cohanzick Management, LLC and CrossingBridge Advisors, LLC

Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) (“Adastra” or the “Company”), a leading cannabis company focused on processing, adult-use and medical sales, organoleptic testing and analytical testing, is pleased to report financial results for the three and six months ended June 30, 2022.